Formosa Pharmaceuticals, Inc.’s Post

Exciting News for the Glaucoma Community! 👀 Glaukos Corporation's innovative iDose TR implant is now commercially available. iDose bridges the gap between surgical & pharmaceutical Glaucoma treatment, being an implantable device that administers minute doses of Travopost directly to the target tissue to lower IOP for extended periods. This device based approach eliminates issues of patience non-adherence and reduces side-effects sustained from the direct application of drugs to the eye for long periods of time. Jay Katz, Glaukos's CMO described this launch as a "Monumental Step forward that we've been waiting for and anticipated for years". It will be interesting to see how this product launch will alter the way ophthalmologists approach the treatment of Glaucoma. https://lnkd.in/gmbtzp9p #glaucoma #ophthalmology #innovation #medicaldevices

#NEWS: Johnson & Johnson has co-led the Series D funding of Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, to treat presbyopia in adults.    Presbyopia, the gradual loss of the eye’s ability to focus on near objects, which begins to affect most adults sometime after the age of 40, impacts 128 million people in the US, and 1.9 billion people globally increasing to 2.1 billion by 2030.    Our investment in Orasis Pharmaceuticals explores a novel and flexible treatment option for adults to manage their presbyopia, building on our robust offering of innovative solutions in this area of high need.    We’re excited for this investment in presbyopia innovation as it further supports our efforts to transform the patient experience and create new standards of care in ophthalmology. Learn More: https://lnkd.in/eb8YzwHE

Fascinating read! Delving into the intricacies of pharmaceutical regulations can be as complex as the compounds themselves. The FDA's latest product specific guidance on oxymetazoline hydrochloride ophthalmic solution certainly keeps us on our toes. It's fascinating to witness the intersection of innovation and regulatory standards in this space. RVL Pharmaceuticals' petition adds another layer to this dynamic landscape, prompting us to ponder the evolving nature of drug development and compliance. #citizenpetition #generics #ANDA #bioequivalence #productspecificguidance

Lupin Launches First Generic of Pred Forte® in the United States Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte® Lupin has commenced shipment with a 180-day CGT exclusivity Launch of the first generic version of Pred Forte® (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte® Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroidresponsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte® had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024).

#Malignant #Melanoma #Treatment Market: By Stage (Stage 0, Stage I, Stage II, Stage III, Stage IV, Recurrent), By Therapy (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Inhibitors), By Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generic Drugs), and Region :Cumulative Growth Opportunities Analysis, Size, Share, Trends, and Industry Forecast Till 2030. By: Analytical Market Research Read More Info:https://lnkd.in/daPQb5-b Key Players: Biogen (US), Bristol Myers Squibb (US), Enzon Pharmaceuticals (US), GSK plc (UK), Aptose Biosciences, Inc. (Canada), Merck KGaA, Darmstadt, Germany (Germany), ONO PHARMACEUTICAL CO., LTD. (Japan), Daiichi Sankyo US (Japan), Reliance Industries Limited (India). #marketgrowth #marketshare #marketsize #marketdemands #marketforecast #marketstretargy #marketanalysis #markettrends #market

World Braille Day is observed every year on January 4th on account of Louis Braille’s birthday. This day is a reminder to highlight the importance of accessibility and independence for visually impaired people. Partial or moderate visual impairments like glaucoma, diabetic retinopathy, and ocular disorders can be cured with the help of ophthalmic drugs. These drugs are widely used to treat age-related eye disorders and form a significant segment of the pharmaceutical industry. Accordingly, the global ophthalmic drugs market is expected to rise at a CAGR of 6.64% during the forecast period 2023-2030. This World Braille Day, get the latest insights regarding ophthalmic drugs or request a custom report here: https://lnkd.in/d3TsytcN . . . AbbVie Bausch Health Companies Inc. Johnson & Johnson Novartis #brailleday #braille #ophthalmicdrugs #opthalmology #healthcare #pharmaceuticals #eyehealth #visualimpairment #marketinsights #tritonmarketresearch

“AI At Johnson & Johnson – Current Investments” https://lnkd.in/eYPMQEA Johnson & Johnson (J&J) is the largest pharmaceutical firm by revenue. In this article, we’re going to take a look at the known AI-related investments of Johnson & Johnson in the two areas where they seem to be most active today: - Drug development - Robotic surgery #artificialintelligence #AI #drugdevelopment #roboticsurgery #lifesciences #pharmaceutical #healthcare

#Biosimilars compete with high-cost specialty brand biologics, which represent only 2% of all prescriptions but account for more than half of all pharmaceutical spending. Despite their potential cost-savings, biosimilar adoption has been slow. To learn how biosimilars aim to enhance patient access and affordability of treatment options, visit: https://ogn.llc/6041lio4l #OrganonBiosimilars #Dermatologists #Oncologists #Immunologists #Rheumatologists #Gastroenterologists #Opthamologists

Glaukos Announces Second Quarter 2024 Financial Results ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2024. Key highlights include: Record net sales of $95.7 million in Q2 2024 increased 19% year-over-year on a reported basis and 20% year-over-year on a constant currency basis. Glaucoma record net via Business Wire Health: Medical Devices News

Pacira BioSciences, Inc. lost a ruling to Jiangsu Hengrui Pharmaceuticals Co. and its eVenus Pharmaceutical Laboratories, Inc. unit as a federal judge canceled a patent for Exparel, a long-acting injectable painkiller for managing postsurgical pain. Judge Madeline Cox Arleo issued the order Friday in the U.S. District Court, District of New Jersey. She gave the parties seven days to file a joint proposed redacted version of her opinion, issued concurrently under seal. The invalidation of US Patent No. 11,033,495, which would’ve expired in January 2041, mooted Pacira’s infringement claim, according to the order. Arleo also said that “no finding of enablement or inequitable conduct shall issue.” Pacira’s stock plunged Friday by more than 47% to close trading at $11.70 a share. The ruling follows a bench trial that began in early April. The FDA approved Jiangsu’s copy July 1, sending Pacira shares plunging by as much as 28%, its worst drop on record at the time. Arleo noted during a status teleconference last month that eVenus had agreed not to launch its copy until Aug. 1 to give the court time to issue a ruling. She said in a July 31 text order that, “in light of personal circumstances,” she would issue a ruling “no later than” Friday. Exparel had sales of $538.1 million in 2023, 79.7% of Pacira’s revenue, according to data compiled by Bloomberg. Pacira on July 30 reported sales of $269.3 million in the first six months of 2024, up from $265.5 million during the same period in 2023. Click for full coverage.